Skip to main content

Table 3 Transcript levels of prognosis gene markers in B cells of CLL patients before treatment with fludarabine.

From: Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia

 

CLL-11

CLL-2

CLL-3R2

CLL-4

CLL-5

CLL-6R2

ATM

1.00 3

1.10

0.42 3

1.91

0.52 3

2.32

BLM

1.00

0.54

1.32

0.79

0.92

2.06

CDK2AP1

1.00

0.52

2.59

0.33

0.70

1.75

DCLRE1A

1.00

1.26

2.84

0.12

1.27

3.11

MYC

1.00

1.36

20.33 4

0.95

1.42

34.39 4

PCNA

1.00

0.43

2.85

0.59

0.61

1.49

SULF2

1.00

0.4

72.6

4.8

2.5

157.4

TP53

1.00

0.94

0.04 5

1.12

0.70

0.62 5

UMPS

1.00

0.73

1.33

0.71

0.73

1.53

XPC

1.00

0.98

0.23

1.43

1.56

0.43

  1. 1 Ct values from this patient were used for normalization to compare expression levels between patients with the ΔΔCt calculation method.
  2. 2 Patient number followed by "R" indicates the refractoriness character to fludarabine.
  3. 3 A mono-allelic deletion on 11q22 was observed.
  4. 4 A gain on 8q was observed.
  5. 5 A mono-allelic deletion on 17p13 was observed.